Health Care

Arcutis Biotherapeutics insider sale shows routine RSU tax‑withholding, not a sell‑off, while the company’s robust SLE drug, IL‑6 pipeline, and $3.33 B market cap keep investor sentiment positive.

CEO Loeillot Olivier’s disciplined 10b5‑1 purchase of 5,426 REPLIGEN shares signals strong management confidence and a long‑term growth outlook for the biotech firm.

HUMACYTE insider buying shows top execs bullish on its bio‑engineered skin grafts, even as the stock slides; explore short‑term momentum vs. long‑term regulatory upside.

Insightful review of Dennis Cho’s August 19 sale at Twist Bioscience – why it’s a planned divestment, not a red flag, and what it means for investors.

Valente Manuela’s $3.20 insider buy of 10k SOPHiA GENETICS shares amid a strong rally signals confidence in the AI‑powered genomic analytics firm’s undervalued future.

Regeneron insider Joseph Lara’s recent buy‑sell pattern signals confidence while adding liquidity, hinting at potential strategic moves for shareholders.

Tempus AI insider sell‑to‑cover: CEO Eric Lefkofsky liquidates 132,591 shares at $49.61, a routine tax‑cover move that keeps his long‑term stake intact as the company pushes AI‑driven oncology trials toward FDA breakthrough status.

Insider buys spike as Amylyx’s CEO and team back Phase‑3 success, signaling confidence before avexitide’s FDA filing and potential market entry.

Insider CFO Blumberg Scott’s 10‑b‑5‑1 trades reveal disciplined buying, profit‑taking, and confidence in CERIBELL’s AI‑driven diagnostics—key insights for investors.

Viridian Therapeutics insider buying signals confidence: Chief Legal Officer sells and buys shares to balance liquidity and long‑term stake, reflecting bullish outlook.